Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

241

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimers Disease

Interventions

DRUG: RO7126209
DRUG: Placebo

Sponsor

Hoffmann-La Roche